Please use this identifier to cite or link to this item:
http://hdl.handle.net/11375/26538
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kavsak PA | - |
dc.contributor.author | Hammarsten O | - |
dc.contributor.author | Worster A | - |
dc.contributor.author | Smith SW | - |
dc.contributor.author | Apple FS | - |
dc.date.accessioned | 2021-06-08T17:57:27Z | - |
dc.date.issued | 2021-01-08 | - |
dc.identifier.issn | 0009-9147 | - |
dc.identifier.issn | 1530-8561 | - |
dc.identifier.uri | http://hdl.handle.net/11375/26538 | - |
dc.description.abstract | <jats:title>Abstract</jats:title> <jats:sec> <jats:title>Background</jats:title> <jats:p>The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that emerged late in 2019 causing COVID-19 (coronavirus disease-2019) may adversely affect the cardiovascular system. Publications from Asia, Europe, and North America have identified cardiac troponin as an important prognostic indicator for patients hospitalized with COVID-19. We recognized from publications within the first 6 months of the pandemic that there has been much uncertainty on the reporting, interpretation, and pathophysiology of an increased cardiac troponin concentration in this setting.</jats:p> </jats:sec> <jats:sec> <jats:title>Content</jats:title> <jats:p>The purpose of this mini-review is: a) to review the pathophysiology of SARS-CoV-2 and the cardiovascular system, b) to overview the strengths and weaknesses of selected studies evaluating cardiac troponin in patients with COVID-19, and c) to recommend testing strategies in the acute period, in the convalescence period and in long-term care for patients who have become ill with COVID-19.</jats:p> </jats:sec> <jats:sec> <jats:title>Summary</jats:title> <jats:p>This review provides important educational information and identifies gaps in understanding the role of cardiac troponin and COVID-19. Future, properly designed studies will hopefully provide the much-needed evidence on the path forward in testing cardiac troponin in patients with COVID-19.</jats:p> </jats:sec> | - |
dc.publisher | Oxford University Press (OUP) | - |
dc.subject | COVID-19 | - |
dc.subject | acute care | - |
dc.subject | cardiac troponin | - |
dc.subject | risk stratification | - |
dc.subject | Biomarkers | - |
dc.subject | COVID-19 | - |
dc.subject | Cardiovascular Diseases | - |
dc.subject | Humans | - |
dc.subject | Pandemics | - |
dc.subject | SARS-CoV-2 | - |
dc.subject | Sensitivity and Specificity | - |
dc.subject | Troponin | - |
dc.title | Cardiac Troponin Testing in Patients with COVID-19: A Strategy for Testing and Reporting Results | - |
dc.type | Article | - |
dc.date.updated | 2021-06-08T17:57:25Z | - |
dc.date.embargo | 2022-06-08 | - |
dc.date.embargoset | 12 months | - |
dc.identifier.doi | https://doi.org/10.1093/clinchem/hvaa225 | - |
Appears in Collections: | Faculty Publications (via McMaster Experts) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
Cardiac Troponin Testing in Patients with COVID-19 A Strategy for Testing and Reporting Results.pdf | Published version | 631.62 kB | Adobe PDF | View/Open |
Items in MacSphere are protected by copyright, with all rights reserved, unless otherwise indicated.